SelectQuote is asking investors to look through a smaller company and a sub-dollar listing gap and pay for cash that the pharmacy engine is only now starting to throw off. Management spent fiscal 2026 proving that Healthcare Services, built around the SelectRx specialty pharmacy, can scale profit even as Medicare Advantage carriers pull back volume and the Inflation Reduction Act compresses pharmacy list prices. The residual common claim sits underneath an expensive stack of term debt and senior preferred that still compounds. The investment debate is whether doubling operating cash in fiscal 2027 is enough to accrete through that stack before preferred dividends and a New York Stock Exchange bid-price clock consume what little equity value remains.
The tension is visible in the print. Consolidated revenue rose to just over $1.62 billion, yet adjusted earnings before interest, taxes, depreciation, and amortization, a cash-earnings proxy that strips specified items, fell to $109 million. Operating cash flipped to an inflow of $31.9 million after an $11.7 million outflow a year earlier. After preferred dividends and accretion, common holders booked an $11.6 million loss even as consolidated net income printed $62.2 million. That gap is the capital structure talking, not the operating model.
Fourth-quarter revenue slipped and the quarter swung to a net loss, but sequential pharmacy profitability and a thinner cash burn are the evidence management wants the market to price. Guidance for the new fiscal year cuts the top line by about fourteen percent at the midpoint while asking for more than $60 million of operating cash. The question the next enrollment season has to answer is whether SelectRx margins actually double and whether the Senior book can stay profitable on fewer approved policies without starving the pharmacy of new members.